Introduction
In solid organ transplantation, immune rejection remains one of the main causes of graft failure. Traditionally, immunosuppressive therapies have focused on suppressing or depleting T cells. However, increasing evidence highlights the central role of B cells, plasma cells, and antibodies in mediating immune responses against transplanted organs.
B cells contribute to transplant rejection not only through antibody production but also by acting as antigen-presenting cells and modulators of T-cell responses. The emergence of donor-specific antibodies (DSA) and antibody-mediated rejection (AMR) has shifted attention toward targeting the humoral immune system. This is particularly relevant in highly sensitized patients or in cases of HLA-incompatible transplantation, where the risk of rejection is significantly increased.
At the same time, research has shown that B cells are not purely pathogenic. Certain subsets play regulatory roles and may contribute to transplant tolerance. This dual function has led to a paradigm shift: modern strategies aim not only to deplete B cells but also to modulate their activity in a more selective and controlled manner.
B Cells in Immune Responses
B cells are a heterogeneous population of lymphocytes with distinct functions and phenotypes. Two major subsets are typically described:
- B1 cells: Located mainly in the peritoneal and pleural cavities, they produce low-affinity “natural” antibodies without T-cell help.
- B2 cells: Generated in the bone marrow, they circulate through secondary lymphoid organs such as the spleen and lymph nodes, where they encounter antigens and become activated.
Activation and Differentiation
B cell activation occurs when their B-cell receptor (BCR) binds a specific antigen. After activation, B cells:
- Present antigen via MHC class II molecules to T cells.
- Receive help from T cells, particularly from T follicular helper (Tfh) cells.
- Undergo proliferation and differentiation.
Activated B cells can follow different pathways:
- Extrafollicular response: Rapid differentiation into plasmablasts producing low-affinity antibodies.
- Germinal center reaction: Leads to:
- Somatic hypermutation
- Class-switch recombination
- Selection of high-affinity B cells
This process generates:
- Memory B cells (long-term immunity)
- Plasma cells (antibody-secreting cells)
Some plasma cells become long-lived and reside in the bone marrow, continuously producing IgG antibodies. These cells are critical in maintaining long-term alloimmune responses.
Antibodies produced by plasma cells are key mediators of graft damage. Their structure includes:
- Fab region: Binds specific antigens (donor HLA molecules)
- Fc region: Mediates effector functions
Effector Mechanisms
Antibodies contribute to rejection through:
- Activation of the complement system
- Engagement of Fc receptors (FcγRs) on immune cells
- Induction of:
- Macrophage phagocytosis
- Neutrophil activation
- Natural killer (NK) cell–mediated cytotoxicity (ADCC)
These mechanisms result in inflammation and tissue injury within the graft, contributing to both acute and chronic AMR.
A regulatory receptor, FcγRIIB, counterbalances these effects by inhibiting immune activation.
BAFF and B Cell Survival
The cytokine BAFF (B-cell activating factor) plays a critical role in B cell survival and maturation. It interacts with receptors such as:
- BAFF-R
- TACI
- BCMA
High levels of BAFF can lead to excessive B cell survival, hypergammaglobulinemia, and autoimmune-like conditions.
In transplantation, BAFF contributes to:
- Maintenance of memory B cells
- Survival of plasma cells
- Persistence of alloantibody production
Regulatory B Cells: A Protective Role
Not all B cells promote rejection. A subset known as regulatory B cells (Bregs) produces anti-inflammatory cytokines such as IL-10.
Functions of regulatory B cells include:
- Suppression of immune responses
- Inhibition of T cell activation
- Promotion of immune tolerance
Evidence suggests that these cells may contribute to transplant tolerance, making them an important consideration in therapeutic strategies. Depleting all B cells indiscriminately may therefore have negative consequences.
Therapeutic Strategies Targeting B Cells and Antibodies
Modern transplantation therapies aim to control the humoral immune response through multiple approaches:
1. B Cell Depletion
Agents targeting B cells include:
- Anti-CD20 monoclonal antibodies ( rituximab)
- Anti-CD19 antibodies
- Anti-CD52 antibodies
These therapies reduce circulating B cells but may not eliminate long-lived plasma cells.
2. Inhibition of B Cell Activation and Survival
Targeting pathways involved in B cell survival:
- BAFF inhibitors ( belimumab)
- BAFF/APRIL blockade (atacicept)
These agents reduce B cell activation and antibody production, particularly in newly formed B cells.
3. Plasma Cell Depletion
Plasma cells are the primary source of alloantibodies. Strategies include:
- Proteasome inhibitors (e.g., bortezomib)
- Induce apoptosis of plasma cells
- Reduce antibody production
- Targeting plasma cell surface markers (e.g., CD138)
4. Antibody Removal and Functional Inhibition
- Plasmapheresis: Removes circulating antibodies
- Intravenous immunoglobulin (IVIG):
- Modulates immune responses
- Reduces antibody activity
- Interferes with complement activation
- Complement inhibitors (eculizumab):
- Block complement-mediated graft injury
Clinical Applications in Transplantation
These strategies are applied in several clinical contexts:
- Desensitization protocols: Before HLA-incompatible transplantation
- Treatment of AMR: Acute or chronic antibody-mediated rejection
- Induction therapy: To prevent early rejection
- Management of sensitized patients: Those with pre-existing antibodies
However, responses vary, and combination therapies are often required for optimal results.
Challenges and Considerations
Despite therapeutic advances, several challenges remain:
- Risk of over-immunosuppression
- Loss of regulatory B cell function
- Limited efficacy against long-lived plasma cells
- Variability in patient response
- Lack of large-scale randomized controlled trials for some therapies
Additionally, some treatments may paradoxically increase rejection risk by disrupting immune regulation.
Conclusion
B cells and antibodies play a central role in transplant immunology, extending beyond simple antibody production to include antigen presentation and immune regulation. While targeting B cells offers significant therapeutic potential, it requires a nuanced approach to avoid disrupting beneficial immune functions.
Future strategies will likely focus on:
- Selective targeting of pathogenic B cell subsets
- Preservation of regulatory B cells
- Combination therapies for better control of alloimmunity
Advances in this field will be essential to improving long-term transplant outcomes and reducing graft rejection.